Top 5 biggest drivers of new specialty drug spending

specialty drug spending (ano lobb)

The IMS Institute's report "Declining Medicine Use and Costs: For Better or Worse? A review of the Use of Medicines in the United States in 2012" is out. On the whole, drug spending in the US in 2012 was down – a drop that was mostly attributable to patent expiries in various therapy areas. However, spending on new medicines (i.e. those launched in the prior 24 months) actually increased – and this rise was largely driven by dramatically increased sales of new specialty medicines. The 5 specialty drugs that were the biggest drivers of this increase were:

  1. Telapevir (Incivek) – Hepatitis C – Vertex Pharmaceuticals
  2. Aflibercept (Eylea) – Wet age-related macular degeneration – Regeneron
  3. Denosumab (Xgeva) – Bone metastasis in cancer – Amgen
  4. Fingolimod (Gilenya) – Multiple sclerosis – Novartis
  5. Ipilimumab (Yervoy) – Inoperable or metastatic melanoma – Bristol-Myers Squibb

Click here to read the full report from the IMS Institute: "Declining Medicine Use and Costs: For Better or Worse? A review of the Use of Medicines in the United States in 2012" (free registration required).

Why not join ourdiscussion on LinkedIn, or leave a comment below. Want more from Total BioPharma? Sign up to our newsletter – it doesn't cost anything and only takes a minute.

Leave a Reply

Your email address will not be published. Required fields are marked *